Trials / Completed
CompletedNCT04871945
Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis
Evaluation of Protective Antibody Production After COVID-19 Vaccination Among Patients Under Hemodialysis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 31 (actual)
- Sponsor
- Hanyang University Seoul Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The aim of the study is to evaluate the level of neutralizing antibody against SARS-CoV-2 after COVID-19 vaccination in patients under hemodialysis. To this end, the level of neutralizing antibody of patients under hemodialysis is compared to that of healthy population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA) | The antibody level will be measured by the above mentioned methods. The trial drugs are not used but the vaccine that included in National Immunization Program for COVID-19 in Korea will be used for the study. |
Timeline
- Start date
- 2021-04-20
- Primary completion
- 2021-09-30
- Completion
- 2021-10-31
- First posted
- 2021-05-04
- Last updated
- 2022-03-17
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04871945. Inclusion in this directory is not an endorsement.